RNXT
HEALTHCARERenovoRx Inc
AI Insight
What's Moving RNXT Today?
No stock-specific AI insight has been generated for RNXT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.70$1.45
$0.91
Fundamentals
Market Cap$41M
P/E Ratio—
EPS$-0.33
Dividend Yield—
Dividend / Share—
ROE-100.5%
Profit Margin—
Debt / Equity—
Trading
Volume164K
Avg Volume (10D)—
Shares Outstanding45.1M
RNXT News
22 articles- iAccess Alpha Virtual Best Ideas Summer Investment Conference Begins TodayYahoo Finance·Jun 23, 2026
- iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 23–24, 2026Yahoo Finance·Jun 18, 2026
- RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic CancerYahoo Finance·Jun 11, 2026
- RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rdYahoo Finance·Jun 4, 2026
- RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic CancerTradingView·May 28, 2026
- RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic CancerYahoo Finance·May 28, 2026
- RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual MeetingYahoo Finance·May 26, 2026
- RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20thYahoo Finance·May 19, 2026
- RenovoRx, Inc. Q1 2026 Earnings Call SummaryMoby·May 15, 2026
- RenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic ExpansionYahoo Finance·May 15, 2026
- RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 14, 2026
- Record Q1 2026 revenue and TIGeR-PaC progress at RenovoRx (NASDAQ: RNXT)Stock Titan·May 14, 2026
- RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-QuarterYahoo Finance·May 14, 2026
- Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag EstimatesYahoo Finance·May 7, 2026
- RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseYahoo Finance·May 7, 2026
- Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 6, 2026
- Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 5, 2026
- RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ETYahoo Finance·Apr 29, 2026
- RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual MeetingYahoo Finance·Apr 23, 2026
- Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific MeetingYahoo Finance·Apr 14, 2026
- RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa VasorumYahoo Finance·Apr 8, 2026
- RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026GlobeNewswire Inc.·Apr 1, 2026
All 22 articles loaded
Price Data
Open$0.89
Previous Close$0.91
Day High$0.93
Day Low$0.89
52 Week High$1.45
52 Week Low$0.70
52-Week Range
$0.70$1.45
$0.91
Fundamentals
Market Cap$41M
P/E Ratio—
EPS$-0.33
Dividend Yield—
Dividend / Share—
ROE-100.5%
Profit Margin—
Debt / Equity—
Trading
Volume164K
Avg Volume (10D)—
Shares Outstanding45.1M
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. The company is headquartered in Los Altos, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—